Boehringer Ingelheim Reports Results of Pradaxa (dabigatran etexilate mesylate) for the Management of Venous Thromboembolism in Children

 Boehringer Ingelheim Reports Results of Pradaxa (dabigatran etexilate mesylate) for the Management of Venous Thromboembolism in Children

Boehringer Ingelheim Reports Results of Pradaxa (dabigatran etexilate mesylate) for the Management of Venous Thromboembolism in Children

Shots:

  • The P-IIb/III DIVERSITY study involve assessing of Pradaxa vs SOC (heparin or vitamin K antagonist) in children with acute VTE requiring anticoagulation therapy for 3mos. aged ≤18yrs. resulted in non-inferiority to the SOC in pediatric patients at high risk of VTE with comparable bleeding rates
  • The P-III second study assess direct oral anticoagulant (DOAC) for the secondary prevention of VTE in ~200 children with persistent VTE risk factors for 12mos. resulted in the reduction of recurrent VTEs and major bleeding event
  • Pradaxa (PO) is an anticoagulant indicated to treat & prevent blood clots and stroke in people with atrial fibrillation with its safety & efficacy proven in RE-VOLUTION study in adults with VTE

Click here to read full press release/ article | Ref: PRNewswire | Image: Blue Sky Exhibits

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post